Opioid treatment moves to your local pharmacy—with safeguards
S. 4941 — Modernizing Opioid Treatment Access Act 2.0 of 2026 · Filed by Ed Markey (D-MA) · 7 cosponsors · Introduced Jun 24, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands access to methadone for opioid addiction treatment by allowing qualified addiction medicine doctors and psychiatrists to prescribe methadone through regular pharmacies (not just specialized opioid treatment programs), with electronic prescribing and patient informed consent. States can opt out by requesting the Attorney General stop registering prescribers in their jurisdiction.
Why we flagged it
The bill's core mechanism is removing regulatory barriers to methadone dispensing through pharmacies to expand treatment access for opioid use disorder—a public health objective, not a narrow carve-out or corporate benefit.
What the text implies
- Pharmacy chains and mail-order pharmacies may see increased volume and revenue from methadone dispensing, creating a secondary market incentive that could influence industry support for the bill.
- State opt-out authority creates a patchwork of access—some states may restrict the program, leaving residents in those states with fewer treatment options than neighboring states.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmacy chains and independent pharmacies; pharmaceutical distributors; telemedicine platforms